Information  X 
Enter a valid email address

Amryt Pharma PLC Ord 1P (AMYT)

Date Time Source Announcement
10 May 2018 7:00 am
RNS
Exclusive Lojuxta? Licence Expanded
09 May 2018 2:48 pm
RNS
Holding(s) in Company
08 May 2018 7:00 am
RNS
Holding(s) in Company and Lock-in agreement
04 May 2018 7:00 am
RNS
Posting of Annual Report 2017 and Notice of AGM
17 Apr 2018 7:00 am
RNS
Final Results
15 Mar 2018 7:00 am
RNS
Trading update & Gene therapy agreement
06 Mar 2018 7:00 am
RNS
Senior Management Appointment
  7:00 am
RNS
Distribution Agreement for Lojuxta in Middle East
02 Mar 2018 7:00 am
RNS
Notice of Trading Update
30 Jan 2018 7:00 am
RNS
New Distribution Agreement Signed
24 Jan 2018 7:00 am
RNS
Senior Management Team Appointment
10 Jan 2018 7:00 am
RNS
New Distribution Agreement Signed
08 Jan 2018 7:00 am
RNS
Distribution Agreement Signed Covering Switzerland
20 Dec 2017 7:00 am
RNS
Senior Management Team Appointment
01 Dec 2017 7:00 am
RNS
Grant of Options & PDMR Dealings
20 Nov 2017 4:35 pm
RNS
Price Monitoring Extension
13 Nov 2017 7:00 am
RNS
Distribution Agreement Signed in Saudi Arabia
13 Oct 2017 3:29 pm
RNS
Holding(s) in Company
11 Oct 2017 7:00 am
RNS
Director Share Purchases
  7:00 am
RNS
Holding(s) in Company
09 Oct 2017 12:13 pm
RNS
Result of General Meeting & Completion of Placing
21 Sep 2017 7:00 am
RNS
Placing to raise EUR 15m
04 Sep 2017 7:00 am
RNS
Interim Results
31 Aug 2017 7:00 am
RNS
Attendance at Rodman & Renshaw Conference
30 Aug 2017 7:00 am
RNS
Senior Management Appointment
23 Aug 2017 8:30 am
RNS
Notice of Results
25 Jul 2017 7:00 am
RNS
Highly positive long-term study results - Lojuxta
25 May 2017 11:49 am
RNS
Result of AGM
  7:00 am
RNS
AGM Statement
27 Apr 2017 7:00 am
RNS
Study Results of Real-World Experience of Lojuxta
24 Apr 2017 7:00 am
RNS
First Patient Enrolled
10 Apr 2017 5:21 pm
RNS
Director/PDMR Shareholding
06 Apr 2017 4:13 pm
RNS
Posting of Annual Report 2016 and Notice of AGM
30 Mar 2017 7:00 am
RNS
Final Results
28 Mar 2017 7:00 am
RNS
Phase 3 Clinical Trial for AP101 commenced
27 Mar 2017 7:00 am
RNS
Senior Management Appointment
08 Mar 2017 7:00 am
RNS
Notice of Results
06 Mar 2017 7:00 am
RNS
AP101 trial discussions completed with FDA & EMA
09 Feb 2017 7:00 am
RNS
Directorate Change
07 Feb 2017 7:00 am
RNS
Grant of patent in Japan for AP101 (Episalvan)
06 Feb 2017 7:00 am
RNS
Pre-clinical study results
05 Dec 2016 7:00 am
RNS
Transformational Licence Agreement
02 Dec 2016 7:00 am
RNS
EUR20m Facility with European Investment Bank
07 Nov 2016 7:00 am
RNS
Orphan drug designation for Acromegaly Compound
19 Sep 2016 7:00 am
RNS
Appointment of Chief Medical Officer
13 Sep 2016 7:00 am
RNS
Grant of US patent for lead drug, Episalvan
  7:00 am
RNS
Half-year Report
07 Jul 2016 12:54 pm
RNS
Result of AGM
27 Jun 2016 7:00 am
RNS
Markus Ziener appointed as Non-Executive Director
09 Jun 2016 7:00 am
RNS
Financial Results
02 Jun 2016 4:34 pm
RNS
Notice of Results
21 Apr 2016 4:35 pm
RNS
Holding(s) in Company
19 Apr 2016 7:00 am
RNS
Admission to trading on AIM and ESM
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t